Arax Advisory Partners’s Q32 Bio QTTB Stock Holding History

Arax Advisory Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Sell	1,111 -37	-3%	-$309	﹤0.01%	4171
2026 Q1	$7.37K	Buy	1,148 +37	+3%	+$176	﹤0.01%	2612
2025 Q4	$3.69K	Sell	1,111 -104	-9%	-$294	﹤0.01%	3009
2025 Q3	$2.4K	Buy	1,215 +104	+9%	+$200	﹤0.01%	3075
2025 Q2	$1.66K	Buy	+1,111	New	+$1.89K	﹤0.01%	2630

Other funds holding QTTB

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's QTTB Position: Q2 2026 in Review

Arax Advisory Partners reduced its Q32 Bio (QTTB) stake by 3.2% in Q2 2026, selling an estimated $309 and leaving 1,111 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4171.

Arax Advisory Partners first reported a position in QTTB in Q2 2025 and has held it in 5 quarters since. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

Arax Advisory Partners held 1,111 shares of Q32 Bio worth $14.2K as of Q2 2026.
Arax Advisory Partners sold 37 Q32 Bio shares in Q2 2026, an estimated $309.
Q32 Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4171 holding.
Arax Advisory Partners first reported a position in Q32 Bio in Q2 2025 and has held it in 5 quarters since.
72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.